Johnson & Johnson (JNJ): FY26 Q3 earnings call, Oct 13, 2026
On its Oct 13, 2026 earnings call (FY26 Q3), Johnson & Johnson said 10 of the 16 words Kalshi listed; Parrot’s count agreed with all 16 settlements. Quotes below are at most 25 words each, with timed clips.
UpdatedMarkets
16 words · 10 settled yes · our count agreed on 16 of 16- Kalshi: company speakers + operator
Kalshi
backtest The probabilities on settled rows are a walk-forward backtest: the model as of before each event, computed after Parrot went live; they were not published at the time.
| Word | Result | Our count | All speakers | Agrees | Probability | Clip | Market |
|---|---|---|---|---|---|---|---|
| Ottava | Yes | 12 | 12 | ✓ | 90%n=3+tx from settlement history blended with transcripts | Hear it 12:05, Ottava | – |
| Firefly Bio | Yes | 9 | 9 | ✓ | 45%transcripts from the transcript model | Hear it 6:07, Firefly Bio | – |
| Rybrevant | Yes | 7 | 7 | ✓ | 91%n=3+tx from settlement history blended with transcripts | Hear it 5:13, Rybrevant | – |
| Caplyta | Yes | 4 | 4 | ✓ | 87%transcripts from the transcript model | Hear it 9:14, Caplyta | – |
| Litigation | Yes | 4 | 4 | ✓ | 72%n=2+tx from settlement history blended with transcripts | Hear it 15:26, Litigation | – |
| Procedure | Yes | 3 | 3 | ✓ | 92%n=3+tx from settlement history blended with transcripts | Hear it 12:37, Procedure | – |
| Tecvayli | Yes | 3 | 3 | ✓ | 81%transcripts from the transcript model | Hear it 5:01, Tecvayli | – |
| China | Yes | 2 | 2 | ✓ | 88%n=3+tx from settlement history blended with transcripts | Hear it 20:06, China | – |
| Tariff | Yes | 2 | 2 | ✓ | 86%n=2+tx from settlement history blended with transcripts | Hear it 21:38, Tariff | – |
| Darzalex Faspro | Yes | 1 | 1 | ✓ | 56%n=3+tx from settlement history blended with transcripts | Hear it 17:21, Darzalex Faspro | – |
| Halda Therapeutics | No | 0 | 0 | ✓ | 69%n=3+tx from settlement history blended with transcripts | – | |
| Administration | No | 0 | 0 | ✓ | 42%n=3+tx from settlement history blended with transcripts | – | |
| AI / Artificial Intelligence | No | 0 | 0 | ✓ | 35%n=2+tx from settlement history blended with transcripts | – | |
| Nipocalimab / Lupus | No | 0 | 0 | ✓ | 27%n=3+tx from settlement history blended with transcripts | – | |
| Vaccine | No | 0 | 0 | ✓ | 14%n=3+tx from settlement history blended with transcripts | – | |
| Gene Therapy | No | 0 | 0 | ✓ | 13%n=1+tx from settlement history blended with transcripts | – |
Market prices are mid quotes from Kalshi and Polymarket, shown for context, may be delayed by several minutes and are not a signal. Quotes as of Oct 20, 2026 15:46 UTC.
Transcript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
12 matches for “Ottava”; 5 quoted, at least 25 words apart.
…advanced instrumentation. In July, the U.S. FDA granted De Novo authorization for OTTAVA, the world's first table integrated soft tissue robotic system. This is one…
…Polyphonic, turns procedure data into actionable insights for clinicians. We already signed our first commercial customer for OTTAVA, and we are progressing our development program.
…during high-risk percutaneous coronary intervention. In surgery, we are focused on commercializing OTTAVA following its recent FDA De Novo authorization. We expect adoption and revenue…
…the opportunity to experience firsthand some of our latest innovations, such as OTTAVA. 2026 is on track for another successful year, exceeding expectations set at…
…at what is on the horizon for surgery with the addition of OTTAVA over time. That will be a significant contributor to growth by the…
Where the listed words were said
…that looks like for 2027 and beyond, specifically with a focus on new innovations like OTTAVA when we come together on December 8th. Thank you.
We completed our acquisition of Firefly Bio, adding a promising new degrader antibody conjugate platform that targets drivers of difficult-to-treat cancers, including KRAS. Our ambition…
…early as the second line of treatment. In solid tumors, sales of RYBREVANT increased by 64%, reflecting its strength in lung cancer. By the end…
…complex nervous system disorders. Today, we are the definitive leader in neuropsychiatry. CAPLYTA reached $1 billion in year-to-date sales, making it our 29th billion-dollar platform.…
…year ago. Results in the quarter were impacted by the proposed talc litigation resolution, as well as expenses associated with the Firefly Bio transaction and…
…basis points related to acquisitions. Electrophysiology delivered growth of 4.4%, driven by procedure expansion, commercial execution, and new product performance, partially offset by competitive…
…by share gains across earlier lines of therapy and continued site expansion. TECVAYLI growth was 77.3%, driven by launch uptake and share gains across earlier…
…The decline is more notably driven by ongoing expansion of VBP in China, surgery transformation program outcomes across the portfolio, and Middle East disruption, which…
…and increased intangible asset amortization expense in the Innovative Medicine segment for Intra-Cellular, partially offset by the impact of tariff recoveries in the MedTech business.
Agents: this page as TSV at /api/v1/appearances/johnson-and-johnson:2026-10-13:earnings_call · words: /api/v1/brief?appearance=johnson-and-johnson:2026-10-13:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP